Summary of CHEMOCENTRYX, INC.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 20, 2013, the Compensation Committee (the "Committee") of the Board of Directors (the "Board") of ChemoCentryx, Inc. (the "Company") established the base salaries to be paid to the executive officers listed below (the "Named Executive Officers"), effective January 1, 2013. On February 20, 2013, the Committee also approved cash bonus payments for the 2012 fiscal year to be paid to each of the Named Executive Officers and set target cash bonuses for the 2013 fiscal year for each of the Named Executive Officers.

The new base salaries, 2013 target cash bonus payments, and 2012 actual cash bonus payments are as follows:

                                                                       2013 Base            2013 Target Cash         2012 Actual Cash
Name                                         Title                      Salary                    Bonus                    Bonus
Thomas J. Schall, Ph.D.            President and Chief             $         510,000        $         255,000        $         219,333
                                   Executive Officer

Markus J. Cappel, Ph.D.            Chief Business Officer and      $         354,543        $         124,090        $          96,790
                                   Treasurer

Susan M. Kanaya                    Senior Vice President,          $         372,212        $         130,274        $         101,614
                                   Finance, Chief Financial
                                   Officer and Secretary

Juan C. Jaen, Ph.D.                Senior Vice President,          $         374,929        $         131,225        $         102,356
                                   Drug Discovery and Chief
                                   Scientific Officer

Petrus Bekker, M.D., Ph.D.         Senior Vice President of        $         369,382        $         129,284        $         100,841
                                   Medical and Clinical
                                   Affairs

In addition, on February 20, 2013, Rishi Gupta resigned from the Board. Mr. Gupta's decision to resign from the Board did not result from any disagreement with the Company concerning any matter relating to its operations, policies or practices. On February 20, 2013, the Board approved an amendment to the stock option agreement of Mr. Gupta to accelerate the vesting date of his options to the date of his resignation and permit exercise of his options for a period of 18 months following the date of his resignation.